2QM Stock Overview
A technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Xylo Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.00 |
| 52 Week High | US$4.18 |
| 52 Week Low | US$1.96 |
| Beta | 1.49 |
| 11 Month Change | 0% |
| 3 Month Change | -11.50% |
| 1 Year Change | -52.61% |
| 33 Year Change | -90.48% |
| 5 Year Change | -94.50% |
| Change since IPO | -94.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QM | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 0.9% |
| 1Y | -52.6% | 2.3% | 5.7% |
Return vs Industry: 2QM underperformed the German Medical Equipment industry which returned 2.3% over the past year.
Return vs Market: 2QM underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| 2QM volatility | |
|---|---|
| 2QM Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2QM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2QM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 84 | Liron Carmel | www.medigus.com |
Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease.
Xylo Technologies Ltd Fundamentals Summary
| 2QM fundamental statistics | |
|---|---|
| Market cap | €3.15m |
| Earnings (TTM) | -€14.78m |
| Revenue (TTM) | €84.62m |
0.0x
P/S Ratio-0.2x
P/E RatioIs 2QM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QM income statement (TTM) | |
|---|---|
| Revenue | US$91.72m |
| Cost of Revenue | US$79.88m |
| Gross Profit | US$11.84m |
| Other Expenses | US$27.87m |
| Earnings | -US$16.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.46 |
| Gross Margin | 12.91% |
| Net Profit Margin | -17.47% |
| Debt/Equity Ratio | 28.4% |
How did 2QM perform over the long term?
See historical performance and comparison